What is Arcutis Biotherapeutics, Inc.'s 2029?

Arcutis Biotherapeutics, Inc. (ARQT) reported 2029 of $107M in Q1 2026.

Arcutis Biotherapeutics, Inc. ARQT 2029

2029 at other companies

OrganonOGN

——

BridgeBio PharmaBBIO

——

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Balance sheet

See full

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Cash flow

See full

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Valuation

See full

Market cap$3.29B+57.5%

Profitability

See full

Gross margin90.9%+2.5pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Returns & leverage

See full

Return on equity-28.2%-13.0pp

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s 2029?: Arcutis Biotherapeutics, Inc. (ARQT) reported 2029 of $107M in Q1 2026.